Cargando…

COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India

BACKGROUND AND AIM: The COVID pandemic and countrywide lockdown has had significant impact on patients with inflammatory bowel disease (IBD), with delay in diagnosis, difficulty in access to healthcare and unavailability of drugs. We conducted a telephonic survey to assess this impact. METHODS: Out...

Descripción completa

Detalles Bibliográficos
Autores principales: Kale, Aditya, Shinde, Leela, Sundaram, Sridhar, Patra, Biswa R, Rao, Praveen K, Irtaza, Mohd, Shukla, Akash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829103/
https://www.ncbi.nlm.nih.gov/pubmed/35155822
http://dx.doi.org/10.1002/jgh3.12686
_version_ 1784647995934900224
author Kale, Aditya
Shinde, Leela
Sundaram, Sridhar
Patra, Biswa R
Rao, Praveen K
Irtaza, Mohd
Shukla, Akash
author_facet Kale, Aditya
Shinde, Leela
Sundaram, Sridhar
Patra, Biswa R
Rao, Praveen K
Irtaza, Mohd
Shukla, Akash
author_sort Kale, Aditya
collection PubMed
description BACKGROUND AND AIM: The COVID pandemic and countrywide lockdown has had significant impact on patients with inflammatory bowel disease (IBD), with delay in diagnosis, difficulty in access to healthcare and unavailability of drugs. We conducted a telephonic survey to assess this impact. METHODS: Out of 350, 302 participated in the survey. Demographic data, disease severity at the time of survey, extent of disease, details of therapy, and adherence were noted. A validated questionnaire addressing information source, perception of COVID‐19 situation, contact with healthcare, and adherence to standard precautions was administered telephonically. RESULTS: Out of 350 contacted patients, 302 (86.28%) patients participated in the survey. Median age of cohort was 39 years. Ulcerative colitis (UC) constituted 79%, 16% Crohn's disease (CD), and 5% IBD‐unclassified. At the time of survey, 86.98% patients with UC were in clinical remission and 75.75% of CD patients were generally well. A total of 115 (38%) cases were nonadherent to therapy due to unavailability of medicines (66.38%), financial constraints (25.21%) and inability to reach healthcare facility (3.6%). Disease flare was seen in 14.2% and correlated well with nonadherence. Existing drug therapy was switched to alternative drug in 70 (23.17%) cases due to unavailability (74%). Social media (52.3%) and television (40.4%) were the common sources of information about the pandemic. Telemedicine platforms (WhatsApp and telephone) were used by 180 (59.6%) patients for consultation with good acceptance (81.6%). 87 (28.8%) patients failed to contact healthcare. Apprehension regarding severe COVID infection was noted in 80% while 29% thought that IBD therapy could increase infection risk. Adherence to wearing mask, hand washing, and social distancing was 100%. CONCLUSION: Pandemic resulted in disruption of healthcare visits and medication supply. Majority were concerned about increased risk of COVID‐19 infection and adhered to standard precautions. Mobile phone‐based formats for patient care may be an alternative due to patient acceptance and convenience.
format Online
Article
Text
id pubmed-8829103
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wiley Publishing Asia Pty Ltd
record_format MEDLINE/PubMed
spelling pubmed-88291032022-02-11 COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India Kale, Aditya Shinde, Leela Sundaram, Sridhar Patra, Biswa R Rao, Praveen K Irtaza, Mohd Shukla, Akash JGH Open Original Articles BACKGROUND AND AIM: The COVID pandemic and countrywide lockdown has had significant impact on patients with inflammatory bowel disease (IBD), with delay in diagnosis, difficulty in access to healthcare and unavailability of drugs. We conducted a telephonic survey to assess this impact. METHODS: Out of 350, 302 participated in the survey. Demographic data, disease severity at the time of survey, extent of disease, details of therapy, and adherence were noted. A validated questionnaire addressing information source, perception of COVID‐19 situation, contact with healthcare, and adherence to standard precautions was administered telephonically. RESULTS: Out of 350 contacted patients, 302 (86.28%) patients participated in the survey. Median age of cohort was 39 years. Ulcerative colitis (UC) constituted 79%, 16% Crohn's disease (CD), and 5% IBD‐unclassified. At the time of survey, 86.98% patients with UC were in clinical remission and 75.75% of CD patients were generally well. A total of 115 (38%) cases were nonadherent to therapy due to unavailability of medicines (66.38%), financial constraints (25.21%) and inability to reach healthcare facility (3.6%). Disease flare was seen in 14.2% and correlated well with nonadherence. Existing drug therapy was switched to alternative drug in 70 (23.17%) cases due to unavailability (74%). Social media (52.3%) and television (40.4%) were the common sources of information about the pandemic. Telemedicine platforms (WhatsApp and telephone) were used by 180 (59.6%) patients for consultation with good acceptance (81.6%). 87 (28.8%) patients failed to contact healthcare. Apprehension regarding severe COVID infection was noted in 80% while 29% thought that IBD therapy could increase infection risk. Adherence to wearing mask, hand washing, and social distancing was 100%. CONCLUSION: Pandemic resulted in disruption of healthcare visits and medication supply. Majority were concerned about increased risk of COVID‐19 infection and adhered to standard precautions. Mobile phone‐based formats for patient care may be an alternative due to patient acceptance and convenience. Wiley Publishing Asia Pty Ltd 2022-01-15 /pmc/articles/PMC8829103/ /pubmed/35155822 http://dx.doi.org/10.1002/jgh3.12686 Text en © 2022 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Kale, Aditya
Shinde, Leela
Sundaram, Sridhar
Patra, Biswa R
Rao, Praveen K
Irtaza, Mohd
Shukla, Akash
COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India
title COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India
title_full COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India
title_fullStr COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India
title_full_unstemmed COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India
title_short COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India
title_sort covid‐19 pandemic and inflammatory bowel disease from patients' perspective: a survey from covid epicenter in india
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829103/
https://www.ncbi.nlm.nih.gov/pubmed/35155822
http://dx.doi.org/10.1002/jgh3.12686
work_keys_str_mv AT kaleaditya covid19pandemicandinflammatoryboweldiseasefrompatientsperspectiveasurveyfromcovidepicenterinindia
AT shindeleela covid19pandemicandinflammatoryboweldiseasefrompatientsperspectiveasurveyfromcovidepicenterinindia
AT sundaramsridhar covid19pandemicandinflammatoryboweldiseasefrompatientsperspectiveasurveyfromcovidepicenterinindia
AT patrabiswar covid19pandemicandinflammatoryboweldiseasefrompatientsperspectiveasurveyfromcovidepicenterinindia
AT raopraveenk covid19pandemicandinflammatoryboweldiseasefrompatientsperspectiveasurveyfromcovidepicenterinindia
AT irtazamohd covid19pandemicandinflammatoryboweldiseasefrompatientsperspectiveasurveyfromcovidepicenterinindia
AT shuklaakash covid19pandemicandinflammatoryboweldiseasefrompatientsperspectiveasurveyfromcovidepicenterinindia